Diabetes and Inflammation Laboratory members include:- Diabetes and Inflammation Laboratory The JDRF/Wellcome Trust Diabetes and Inflammation Laboratory (JDRF/WT DIL), centred in the Cambridge Institute for Medical Research, is a multi-disciplinary research programme within the department of Medical Genetics at the University of Cambridge. The current director is John Todd FMedSci FRS and Professor of Medical Genetics at the University of Cambridge. The goals of the JDRF/WT DIL are to identify and characterise the effects of the susceptibility genes for type 1 diabetes in order to better understand the earliest events in human physiology that lead to autoimmune destruction of the insulin-producing beta-cells of pancreas.
Epigenetics of diabetes Type 2 energy metabolism and inflammation. SIRT1 overexpression or activation by resveratrol could improve insulin resistance and SIRT1 activators are being developed for diabetes treatment. The role of other HDACs and the potential use of HDAC inhibitors in diabetes is not very clear. Other treatments look towards an anti-inflammatory agent and HAT inhibitor, curcumin, which in trials ameliorated high glucose-induced inflammatory gene expression and histone acetylation at their promoters as well as changes in HAT and HDAC activities in human monocytes. Metabolic memory is the phenomenon of diabetic vascular stresses persisting after glucose normalization in diabetic patients because of early an glycemic